Literature DB >> 14728990

Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration.

Betina Fiege1, Diana Ballhausen, Lucja Kierat, Walter Leimbacher, Dimitri Goriounov, Bernhard Schircks, Beat Thöny, Nenad Blau.   

Abstract

Tetrahydrobiopterin (BH(4)) is widely used as a therapeutic agent in patients with BH(4) deficiencies and mild forms of phenylketonuria (PKU) and there is an increasing need for the measurement of its plasma concentrations in patients with cardiovascular disorders. We measured BH(4) and total biopterin in dithioerythritol (DTE) pretreated plasma from four adults after oral administration of BH(4) (2, 10, and 20mg/kg body weight) using the differential iodine oxidation method. About 80% (range 64.8-92.2% ) of total biopterin was found as BH(4) when analyzed immediately after blood sampling. Compared with ascorbic acid as an antioxidant, DTE was more protective against oxidation of BH(4), particularly in samples stored over a period of 8 months. Without antioxidant (DTE or ascorbic acid) almost no BH(4) was detected. Furthermore, BH(4) and total biopterin were measured at different time intervals (up to 33 h after oral administration) and pharmacokinetic parameters T(max) (1-4h), C(max) (258.7-259.0 nmol/L biopterin at a dosage of 10mg/kg), and area under the curve (AUC=1708-1958 nmol(*)h/L up to T=10h) were estimated. The elimination half-life time was calculated to be 3.3-5.1h. Doubling the BH(4) dosage to 20mg/kg resulted in 60% higher AUC while sublingual BH(4) application (2mg/kg) resulted in 58-76% higher BH(4) plasma concentrations when compared with oral administration. These preliminary data suggest that in patients with BH(4) cofactor defects and BH(4)-responsive phenylalanine hydroxylase deficiency, BH(4) should be given in at least two to three daily doses and that sublingual administration may lower the required BH(4) dosage and subsequently the cost of treatment. Due to inter individual differences in pharmacokinetic properties, in some patients with hyperphenylalaninemia and mild PKU plasma BH(4) levels may be not high enough to fully activate the liver phenylalanine hydroxylase and thus lower blood phenylalanine levels. Assessment of plasma BH(4) or total biopterin concentrations may be a good way to control the efficacy of the loading test.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14728990     DOI: 10.1016/j.ymgme.2003.09.014

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  35 in total

1.  Severe mucitis after sublingual administration of tetrahydrobiopterin in a patient with tetrahydrobiopterin-responsive phenylketonuria.

Authors:  Thomas Opladen; Marcel Zurflüh; Ilse Kern; Lucja Kierat; Beat Thöny; Nenad Blau
Journal:  Eur J Pediatr       Date:  2005-02-22       Impact factor: 3.183

2.  Simultaneous determination of all forms of biopterin and neopterin in cerebrospinal fluid.

Authors:  Pierre Guibal; Nathalie Lévêque; Diane Doummar; Nicolas Giraud; Emmanuel Roze; Diana Rodriguez; Rémy Couderc; Thierry Billette De Villemeur; Fathi Moussa
Journal:  ACS Chem Neurosci       Date:  2014-04-08       Impact factor: 4.418

3.  Chaperone-like therapy with tetrahydrobiopterin in clinical trials for phenylketonuria: is genotype a predictor of response?

Authors:  Christineh N Sarkissian; Alejandra Gamez; Patrick Scott; Jerome Dauvillier; Alejandro Dorenbaum; Charles R Scriver; Raymond C Stevens
Journal:  JIMD Rep       Date:  2011-12-06

4.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

5.  Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women.

Authors:  Kerrie L Moreau; Amie Meditz; Kevin D Deane; Wendy M Kohrt
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-13       Impact factor: 4.733

6.  Tetrahydrobiopterin augments endothelium-dependent dilatation in sedentary but not in habitually exercising older adults.

Authors:  Iratxe Eskurza; Laura A Myerburgh; Zachary D Kahn; Douglas R Seals
Journal:  J Physiol       Date:  2005-09-01       Impact factor: 5.182

7.  Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria.

Authors:  F K Trefz; D Scheible; H Götz; G Frauendienst-Egger
Journal:  J Inherit Metab Dis       Date:  2008-10-30       Impact factor: 4.982

8.  Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: assessing responsiveness in a model of statistical process control.

Authors:  M Lindner; G Gramer; S F Garbade; P Burgard
Journal:  J Inherit Metab Dis       Date:  2009-06-10       Impact factor: 4.982

9.  A murine model for human sepiapterin-reductase deficiency.

Authors:  Seungkyoung Yang; Young Jae Lee; Jin-Man Kim; Sean Park; Joanna Peris; Philip Laipis; Young Shik Park; Jae Hoon Chung; S Paul Oh
Journal:  Am J Hum Genet       Date:  2006-01-31       Impact factor: 11.025

10.  Human endothelial dihydrofolate reductase low activity limits vascular tetrahydrobiopterin recycling.

Authors:  Jennifer Whitsett; Artur Rangel Filho; Savitha Sethumadhavan; Joanna Celinska; Michael Widlansky; Jeannette Vasquez-Vivar
Journal:  Free Radic Biol Med       Date:  2013-05-23       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.